EUVIMEDEUVIMED entdecken
Crossref

Synergistic Antibacterial Effects of Ceftazidime/Avibactam and Auranofin Combination against Carbapenem-Resistant Klebsiella pneumoniae: In Vitro and in Vivo Evaluation

Lingfei Wang, Yunge Wang, Huijie Yue, Weiping Wang, Yunlong Liu, Guohua Zhou, Ying Wang, Xuejiao Liu, Haiping Wu

Current Microbiology · 2026

DOI: 10.1007/s00284-025-04646-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Microbiology, 2026. Verfasst von Lingfei Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Jinling Hospital, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Ceftazidime, Azabicyclo Compounds, Klebsiella pneumoniae, Anti-Bacterial Agents. Die Arbeit nennt 43 Literaturangaben. Gefördert von: the Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Key Medical Discipline Cultivation Unit, the National Natural Science Foundation of China, Major Science and Technology Projects in Yunnan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To investigate the antibacterial activity of ceftazidime/avibactam (CZA) combined with auranofin (AUR) against Carbapenem-resistant Klebsiella pneumoniae (CRKP) in vitro and in vivo. The minimum inhibitory concentrations (MICs) of CZA and AUR in 40 non-redundant CRKP isolates were determined by broth microdilution method. Drug resistance genes were detected by polymerase chain reaction (PCR). Checkerboard assays, time-kill assays and Galleria mellonella infection models were employed to assess the effect of CZA plus AUR in vitro and in vivo. Additionally, serial subculture experiments were used to evaluate resistance progression. 75.0% (30/40) of clinical isolates exhibited resistance to CZA. The addition of AUR resulted in a remarkable 16-fold reduction in MIC50 (from 128 to 8 mg/L) and MIC90 > 64-fold (from > 2048 to 32 mg/L). Fractional inhibitory concentration index (FICI) analysis demonstrated synergistic activity in 67.5% (27/40) of isolates, including 80.0% (24/30) CZA-resistant strains.At sub-inhibitory concentrations, CZA monotherapy increased the MIC 256-fold, in contrast to CZA combined with AUR treatment which significantly reduced the level of resistance. Monotherapy with either agent showed limited bactericidal effects in vivo, whereas combination therapy achieved complete bacterial eradication within 72-96 h. AUR synergizes with CZA on killing a broad spectrum of carbapenem or CZA resistant Klebsiella pneumoniae both in vitro and in vivo, and slows down the development of CZA resistance. The combination of CZA and AUR might be a potential therapeutic strategy for combating superbugs CZA resistant CRKP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftazidimeAzabicyclo CompoundsKlebsiella pneumoniaeAnti-Bacterial AgentsKlebsiella InfectionsAuranofinCarbapenem-Resistant EnterobacteriaceaeDrug CombinationsMicrobial Sensitivity TestsDrug SynergismAnimalsHumansCarbapenems

Substanzen

CeftazidimeAzabicyclo Compoundsavibactam, ceftazidime drug combinationAnti-Bacterial AgentsDrug CombinationsAuranofinCarbapenems

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Jinling Hospital, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China.
  • Department of Clinical Pharmacy, Jinling Hospital, Affiliated Hospital of Medical School, State Key Laboratory of Analytical Chemistry for Life Science, Nanjing University, Nanjing, Jiangsu, China.
  • Clinical Laboratory, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
  • Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, Jiangsu, China.
  • Yunnan Provincial Key Laboratory of Public Health and Biosafety, Kunming, Yunnan, China.
  • Clinical Laboratory, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China. wynj0216@163.com.

Förderung

  • the Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Key Medical Discipline Cultivation Unit
  • the National Natural Science Foundation of China
  • Major Science and Technology Projects in Yunnan Province

Zitieren

APA

Wang, L., Wang, Y., Yue, H., Wang, W., Liu, Y., Zhou, G., Wang, Y., Liu, X., & Wu, H. (2026). Synergistic Antibacterial Effects of Ceftazidime/Avibactam and Auranofin Combination against Carbapenem-Resistant Klebsiella pneumoniae: In Vitro and in Vivo Evaluation. Current Microbiology. https://doi.org/10.1007/s00284-025-04646-8

Vancouver

Wang L, Wang Y, Yue H, Wang W, Liu Y, Zhou G, et al. Synergistic Antibacterial Effects of Ceftazidime/Avibactam and Auranofin Combination against Carbapenem-Resistant Klebsiella pneumoniae: In Vitro and in Vivo Evaluation. Current Microbiology. 2026. doi:10.1007/s00284-025-04646-8

BibTeX
@article{Wang2026,
  author = {Wang, Lingfei and Wang, Yunge and Yue, Huijie and Wang, Weiping and Liu, Yunlong and Zhou, Guohua and Wang, Ying and Liu, Xuejiao and Wu, Haiping},
  title = {Synergistic Antibacterial Effects of Ceftazidime/Avibactam and Auranofin Combination against Carbapenem-Resistant Klebsiella pneumoniae: In Vitro and in Vivo Evaluation},
  journal = {Current Microbiology},
  year = {2026},
  doi = {10.1007/s00284-025-04646-8}
}
Kostenlos starten →